BMRN vs PBYI · P/E 40, rev $1.76B vs P/E 4.3, rev $56.5M
Biomarin Pharmaceutical Inc (BMRN) versus Puma Biotechnology Inc (PBYI) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Puma Biotechnology Inc (PBYI) is a biotechnology company listed on US.
Latest reported BMRN revenue for 2026-06-30 was $1.76B. Net income was $150.3M. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported PBYI revenue for 2026-06-30 was $56.5M. Net income was $8.2M. Revenue was up 26.1% from 2026-03-31 to 2026-06-30. PBYI currently screens at market cap $165.3M and trailing P/E 4.3.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. PBYI currently screens at market cap $165.3M and trailing P/E 4.3.
Not investment advice. Open the BMRN and PBYI stock pages for the full models.
Not investment advice.